Research into NiV and Hendra virus is crucial for decoding infection mechanisms, improving diagnostics, and accelerating vaccine progress. To support these efforts, Bioss has launched a new series of high-quality recombinant protein products tailored to Nipah and Hendra viruses.

Antibodies are research powerhouses, but batch-to-batch variability can derail experiments. Recombinant monoclonal antibodies (mAbs) are often touted as the
consistency champions. But are they always the best choice? Let's cut through the noise.

Recombinant monoclonal antibodies bring genetic precision, engineering flexibility, and cutting-edge quality control to the lab—dramatically reducing lot-to-lot differences that undermine reproducibility. In this deep dive, we unpack their advantages, explore remaining challenges around glycosylation and cost, and look ahead to AI-driven design and hybrid antibody strategies.